Valuation : Oxeco PLC

Market Cap 6.9M 5.93M 5.56M 5.08M 9.59M 658M 9.63M 65.82M 25.51M 332M 25.92M 25.36M 1.1B P/E 2024
-74.8x
P/E 2025 -0.6x
Enterprise Value 18.63M 15.99M 15.01M 13.71M 25.87M 1.78B 26M 178M 68.85M 897M 69.96M 68.45M 2.97B EV / Sales 2024
2.17x
EV / Sales 2025 0.66x
Free-Float
78.79%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 64 16/10/2025
Director of Finance/CFO - 17/10/2025
Chief Operating Officer - 05/01/2026
Director TitleAgeSince
Director/Board Member - 17/10/2025
Chairman 64 08/09/2025
Director/Board Member - 05/01/2026
Change 5-day change 1-year change 3-year change Capi.($)
+16.93%+13.55%-3.10%+49.42% 39.78B
-2.90%-9.86%-40.72%+144.63% 13.82B
+3.21%-1.19%-17.82%+65.52% 5.55B
+0.64%+4.62%+40.85% - 4.26B
+2.85%+4.25% - - 2.07B
+0.51%-5.13%+1.35%-40.74% 1.53B
-2.10%-2.04%-38.07% - 1.1B
-0.10%+8.49%+41.78%+156.19% 1.03B
+3.08%-0.89%+52.67%+70.79% 1.01B
Average +2.47%-1.09%+4.62%+74.30% 7.79B
Weighted average by Cap. +9.43%-2.85%-8.16%+71.73%

Financials

2024 2025
Net sales 28.65M 24.59M 23.08M 21.08M 39.78M 2.73B 39.97M 273M 106M 1.38B 108M 105M 4.57B 28.43M 24.4M 22.9M 20.92M 39.48M 2.71B 39.67M 271M 105M 1.37B 107M 104M 4.53B
Net income -713K -612K -574K -525K -990K -68M -995K -6.8M -2.63M -34.31M -2.68M -2.62M -114M -11.14M -9.56M -8.97M -8.2M -15.47M -1.06B -15.54M -106M -41.16M -536M -41.83M -40.92M -1.78B
Net Debt 8.6M 7.38M 6.92M 6.32M 11.94M 820M 11.99M 81.94M 31.76M 414M 32.27M 31.57M 1.37B 11.73M 10.07M 9.45M 8.63M 16.29M 1.12B 16.37M 112M 43.34M 564M 44.04M 43.09M 1.87B
Logo Oxeco PLC
Tissue Regenix Group Ltd, formerly Tissue Regenix Group plc, regenerative medicine company specializing in medical devices and allografts. The Company is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue decellularization process, removing DNA and Cellular material to reduce risk of rejection; and BioRinse technology, is a natural bone filler solution. Its proprietary dCELL and BioRinse technologies underpin a focused portfolio of xenograft and allograft products. Its products categories include Musculoskeletal, DermaPure, Soft Tissue-OrthoPure XT, and Birth Tissue. The Musculoskeletal product includes ConCelltrate 100, Conventional GGrafts, MatrixCellect 100 DBM, Matrix OI Cortical Fibers & Fillers, and others. The DermaPure product is a next generation decellularized dermal allograft. The DermaPure product is available in three configurations: DermaPure, DermaPure Non-Oriented, and DermaPure Meshed.
Employees
-